ClinicalTrials.gg
Enrolling by invitationNCT07016737ESO-Nanjing12Updated Jun 12, 2025

Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy

A Phase 3 interventional study of Sintilimab Combined With Docetaxel Monotherapy in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Ye jinjun. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Ye jinjun · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Aug 2024, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma — 9 open to participants now, 9 under way, 4 of them phase 3. sintilimab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
7th of 21
79 · median 52
Started
2024
with 2 others
Phase 3
5 of 21
4 open now
Registered
21st of 21
by date

Among the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, this one is the 7th largest by planned enrollment, is one of 3 that started in 2024, is one of 5 in phase 3, and was the 21st registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

9 of the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

The combination of programmed death receptor 1 (PD-1) inhibitors with chemotherapy has been recognized for the treatment of advanced and metastatic esophageal squamous cell carcinoma (ESCC). To the best of our knowledge, there is no published report to date which analyzes the efficacy and safety of this regimen in the treatment of locally primary-recurrent ESCC patients after definitive chemoradiotherapy or radiotherapy only. This is a prospective clinical study designed to enroll 79 patients. The study will focus on those who have attained a complete response (CR) subsequent to definitive chemoradiotherapy or radiotherapy and have a histologically proven in-field recurrence, with no distant metastases. These patients will receive treatment with a PD-1 inhibitor combined with monotherapy chemotherapy for 4 cycles, followed by a 2-year maintenance treatment with PD-1 inhibitors. During this period, patients diagnosed with esophageal wall thickening and identified as having progressive disease (PD) have the option to undergo salvage radiotherapy in conjunction with a dual-agent chemotherapy for 5 cycles. The primary endpoint of is 2-year after recurrence survival (ARS) rate. The secondary endpoints include the progression-free survival (PFS) and safety.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma (ESCC)

Keywords

  • Esophageal squamous cell carcinoma
  • Local recurrence at the primary tumor site
  • Programmed cell death protein 1
  • Salvage Chemoradiotherapy
  • Immunochemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-1.Age ≥18 years, regardless of gender. 2. confirmed local recurrence of esophageal squamous cell carcinoma after definitive chemoradiotherapy.

3.With or without regional lymph node , but no distant metastasis. 4.Ineligible for surgery or refusal to undergo surgical intervention. 5.Tolerance to chemotherapy, radiotherapy, and immunotherapy. 6. performance status 0-2. 7. ≥3 months. 8.No severe hematopoietic, cardiac, pulmonary, hepatic, renal dysfunction, or immunodeficiency.

Exclusion criteria

Exclusion Criteria:

    1. Esophageal perforation or hematemesis. 2.Distant in patients after definitive chemoradiotherapy. 3.History of drug abuse, chronic alcoholism, or /AIDS. 4.Myocardial infarction within ≤6 months. Patients with myocardial infarction >6 months ago must undergo myocardial thallium scan to confirm absence of myocardial ischemia and obtain cardiologist approval for chemotherapy.

      5.Uncontrolled seizures or psychiatric disorders impairing decision-making capacity.

      6.Severe allergic history or . 7.Other conditions deemed unsuitable for study participation by the investigator.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    This is a prospective clinical study designed to enroll 79 patients. The study will focus on those who have attained a complete response (CR) subsequent to definitive chemoradiotherapy or radiotherapy and have a histologically proven in-field recurrence, with no distant metastases. These patients will receive treatment with a PD-1 inhibitor (sintilimab or camrelizumab 200mg, d1, q3w) combined with monotherapy chemotherapy (paclitaxel 175mg/m2 or docetaxel 75mg/m2 or irinotecan 270mg/m2, d1, q3w) for 4 cycles, followed by a 2-year maintenance treatment with PD-1 inhibitors. During this period, patients diagnosed with esophageal wall thickening and identified as having progressive disease (PD) have the option to undergo salvage radiotherapy (45-50.4 Gy/25-28/F/5-5.5 weeks) in conjunction with a dual-agent chemotherapy (paclitaxel 50 mg/m2, d1 + carboplatin AUC 2, d1, qw) for 5 cycles.

    Drug: Sintilimab Combined With Docetaxel Monotherapy

Interventions

  • DrugSintilimab Combined With Docetaxel Monotherapy

    Drug pages: SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DocetaxelStudies of DocetaxelDocetaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    79 patients will receive treatment with a PD-1 inhibitor (sintilimab or camrelizumab 200mg, d1, q3w) combined with monotherapy chemotherapy (paclitaxel 175mg/m2 or docetaxel 75mg/m2 or irinotecan 270mg/m2, d1, q3w) for 4 cycles, followed by a 2-year maintenance treatment with PD-1 inhibitors. During this period, patients diagnosed with esophageal wall thickening and identified as having progressive disease (PD) have the option to undergo salvage radiotherapy (45-50.4 Gy/25-28/F/5-5.5 weeks) in conjunction with a dual-agent chemotherapy (paclitaxel 50 mg/m2, d1 + carboplatin AUC 2, d1, qw) for 5 cycles.

    Also known as: Sintilimab Combined With Paclitaxel Monotherapy, Sintilimab Combined With Irinotecan Monotherapy, Camrelizumab Combined With Docetaxel Monotherapy, Camrelizumab Combined With Paclitaxel Monotherapy, Camrelizumab Combined With Irinotecan Monotherapy, Paclitaxel Combined With Carboplatin, salvage radiotherapy, Omeprazole, Dexamethasone, Smectite Powder, Loperamide Hydrochloride Capsules, Atropine Hydrochloride, Computed Tomography, Positron Emission Tomography - Computed Tomography, Ultrasound, Gastroscopy, Digital Gastrointestinal Radiography

06

What researchers measure

Primary outcomes

  1. 2-year ARS rate

    the proportion of patients surviving 2 years from the time of recurrence

    Time frame: From date of Immunochemotherapy until the date of death from any cause, assessed up to 24 months

Secondary outcomes

  1. progression-free survival (PFS)

    From Initiation of Immunochemotherapy to Disease Progression

    Time frame: From date of Immunochemotherapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  2. safety assessed by adverse events (TEAEs)

    All treatment-emergent adverse events (TEAEs) related to the investigational drug were documented and graded according to the CTCAE v5.0 criteria during the treatment period.

    Time frame: Up to 2 years after treatment initiation until new treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2027, 37 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
Jun 12, 2025
StartActual
Aug 1, 2024
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2029
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07016737
Lead sponsor
Ye jinjun
Responsible party
Ye jinjun (Chief Physician, M.D., Jiangsu Cancer Institute & Hospital) — Sponsor-investigator
First posted
Jun 12, 2025
Start date
Aug 1, 2024
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Jun 12, 2025

Study contacts

Ye jin jiun
principal investigator · Jiangsu Cancer Institute & Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sintilimab · Docetaxel

Start the discussion